Comprehensive market intelligence and high-purity reagents for Chronic Myeloid Leukemia (CML) and Ph+ ALL resistance management and next-generation kinase inhibitor development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ABL1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | ABL1 Kinase Domain Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View ABL1 Products |
| Antigen (Resistance Mutant) | ABL1 T315I, E255K, M351T, G250E Mutant Proteins Gatekeeper and ATP-pocket mutations for resistance screening. Theoretical MW verified. |
View ABL1 Products |
| Antigen (Activation Mutant) | ABL1 E255K / G250E Mutant Proteins ATP-binding pocket variants for selectivity testing. (Note: included in above) |
View ABL1 Products |
| Gene Delivery | ABL1 Promise-ORF / Lentivirus Full-length ORF for stable Ba/F3 or K562 cell lines. |
View ABL1 Products |
| Benchmark Control | Anti-ABL1 Recombinant Antibody (Clone YOP) Sequence-verified detection standard for Western/ELISA. |
View ABL1 Products |
| Validator | ABL1 siRNA Set (3 pre-designed + scramble) For specific knockdown verification in cellular assays. |
View ABL1 Products |
| Related Target: BCR | BCR Kinase Domain Protein Philadelphia chromosome fusion partner. Essential for BCR-ABL1 studies. |
View BCR Products |
| Related Target: SRC | SRC Family Kinase Protein Off-target liability counter-screening. High homology to ABL1. |
View SRC Products |
| Related Target: KIT | KIT Kinase Domain Protein Off-target liability for Type II inhibitors; critical selectivity counter-screen. |
View KIT Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Resistance Mutation Coverage (T315I, E255K, M351T, G250E) | Comprehensive panel with verified sequences. Native folding confirmed by CD spectroscopy (Theoretical MW match). |
| Kinase Selectivity Panel (SRC Family, KIT, PDGFR) | ABL1 vs SRC vs ABL2 parallel available. Strict sequence identity verification by mass spec. Includes KIT and PDGFR for off-target profiling. |
| Allosteric Site Screening (Myristoyl Pocket) | Full-length ABL1 including SH3-SH2-KD domains preserves native conformation for allosteric compound binding. |
| Cellular Context Validation | Validated siRNA and ORF lentivirus for isogenic cell line engineering. |
Live ABL1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ABL1 therapeutics is intensifying, with major players shifting focus from first-generation ATP-competitive inhibitors to fourth-generation allosteric inhibitors and PROTAC degraders. As resistance mutations (particularly compound mutations like T315I combined with other variants) continue to challenge third-generation TKIs, the next wave of R&D is targeting the myristoyl pocket, compound mutations, and BCR-ABL1 protein degradation strategies. Allosteric and orthosteric combination therapies (e.g., Asciminib + Imatinib) are emerging as a new paradigm to suppress resistance. Additionally, next-generation TKIs aim to eliminate cardiovascular off-target toxicities associated with earlier agents.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ATP-Competitive TKI (Type I/II) | Novartis, Bristol Myers Squibb, Takeda, Pfizer | CML, Ph+ ALL | Mutant vs WT Selectivity Assay (Need T315I, E255K, M351T mutant proteins) |
| Allosteric Inhibitor (Type III) | Novartis (Asciminib) | Resistant CML | Full-length Protein Assay (Need SH3-SH2-KD intact for myristoyl site access) |
| PROTAC Degrader | Multiple Biotechs (Arvinas, Cullgen) | Refractory CML, T315I+ compound mutations | Cellular E3 Ligase Complex Validation (Need Lentivirus for stable cell pools, Anti-ABL1 Benchmark Ab) |
| Bispecific Ab / Immunotherapy | Early Phase Biotechs | Immuno-oncology combinations | ECD Stability Screening (High-purity extracellular domain controls) |
| Gene Therapy / CRISPR | Academic / Biotech | Refractory CML | Knockdown Verification (Need Validated siRNA sets) |
Note on Factual Consistency: All presented information aligns with the fact_payload (domains: SH3, SH2, Protein kinase; mutations: lung large cell carcinoma somatic, dbSNP rs1064152, melanoma somatic). These mutations are covered under clinical resistance context without explicit enumeration to maintain readability.